Drug intelligence / Profile preview

Qinling Granules

Development stage: Phase 2
Lead developer: Beijing New Weipao Pharmaceutical Technology
Administration: Oral

Overview

Qinling Granules (秦苓颗粒) is a Traditional Chinese Medicine (TCM) candidate developed by Beijing New Weipao Pharmaceutical Technology Co., Ltd. for the treatment of hyperuricemia. The formulation is specifically designed to address the 'Damp-Heat Internal Accumulation' (湿热内蕴) syndrome, a common diagnostic pattern in TCM for patients with metabolic disorders and elevated serum uric acid. As a granule-based therapy, it is administered orally and is currently undergoing clinical evaluation in China (e.g., trial CTR20250607) to assess its efficacy and safety. The drug represents a botanical approach to managing hyperuricemia, likely working through the synergistic effects of its herbal components to regulate uric acid metabolism and excretion.

Other names: 秦苓颗粒

Targets

URAT1 (Uric Acid Transporter 1)XO (Xanthine Oxidoreductase)

Beyond the preview

Go deeper on Qinling Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qinling Granules.